GSE129698 SYK inhibition 3 v 4 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE129698_SYK inhibition_3_v_4_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE129698_SYK inhibition_3_v_4_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE129698_SYK inhibition_3_v_4_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE129698_SYK inhibition_3_v_4_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

heme oxygenase 1

Gene

aldo-keto reductase family 1 member C2

Gene

cytochrome P450 family 1 subfamily B member 1

Gene

regulator of cell cycle

Gene

brain expressed X-linked 1

Gene

transforming growth factor beta induced

Gene

pleckstrin homology like domain family A member 1

Gene

complement C3

Gene

protein kinase cAMP-dependent type II regulatory subunit beta

Gene

cell adhesion molecule 1

  • Gene

    heme oxygenase 1


  • Gene

    aldo-keto reductase family 1 member C2


  • Gene

    cytochrome P450 family 1 subfamily B member 1


  • Gene

    regulator of cell cycle


  • Gene

    brain expressed X-linked 1


  • Gene

    transforming growth factor beta induced


  • Gene

    pleckstrin homology like domain family A member 1



  • Gene

    protein kinase cAMP-dependent type II regulatory subunit beta


  • Gene

    cell adhesion molecule 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.